Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Osteologix completes phase I study of NBS-101 for osteoporosis

Sep. 30, 2005

Novel agents for diabetes and related complications reported in recent patent literature

Sep. 29, 2005

Recent patents report novel treatments for obesity

Sep. 29, 2005

Approvable letter for iPlex

Sep. 29, 2005

New data presented on GSK-3 dual inhibitor that demonstrates bone formation

Sep. 29, 2005

Glenmark seeks clearance for phase I trials of DPP-IV inhibitor GRC-8200

Sep. 29, 2005

New data supports the use of exenatide in the treatment of type 2 diabetes

Sep. 28, 2005

Update on AAE-581 in the management of osteoporosis

Sep. 28, 2005

PPARalpha/gamma agonist improves glucose tolerance without stimulating weight gain and adiposity

Sep. 28, 2005

New data indicate superior potency of MB-06322 as a treatment for type 2 diabetes

Sep. 28, 2005

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 21, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 19, 2026
‘Detargeted’ targeted gene therapy improves activity in Pompe
BioWorld
A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...
WHO declares Ebola outbreak a public health emergency of international concern
BioWorld
The threat posed by the Ebola outbreak in the Democratic Republic of Congo has intensified, with the confirmation that it is caused by the Bundibugyo species of...
Nxera Pharma prepares and tests new GPR17 antagonists
BioWorld Science
Nxera Pharma UK Ltd. has identified new uracil nucleotide/cysteinyl leukotriene receptor (GPR17; P2Y-Like) antagonists potentially useful for the treatment of...